AI-driven technologies

Nanobodies offer engineering benefits over traditional antibodies and small molecules, including small size, stability, and specificity.

They offer distinct engineering benefits compared with traditional antibodies and small molecules, including small size, stability, and specificity.

Integrating nanobodies with nanoparticles, dendrimers, liposomes, and viral vectors is being used to improve delivery precision, half-life, and efficacy.

Additionally, to improve nanobody delivery precision, half-life, and efficacy, strategies such as integrating nanobodies with nanoparticles, dendrimers, liposomes, and viral vectors are being employed.

Advanced engineering strategies including intranasal and intrathecal routes, receptor-mediated transport, albumin binding, and focused ultrasound are used to facilitate brain penetration of nanobody therapeutics.

Advanced engineering strategies, including intranasal and intrathecal routes, receptor-mediated transport, plasma protein binding with albumin, and focused ultrasound to facilitate brain penetration.

In preclinical Alzheimer's disease models, nanobodies have been shown to neutralize toxic amyloid-β oligomers, inhibit tau generation and aggregation, and modulate neuroinflammation.

In AD, nanobodies have been shown in preclinical models to neutralize toxic amyloid-β oligomers, inhibit tau generation and aggregation, and modulate neuroinflammation, thereby demonstrating significant therapeutic potential.

Nanobodies are used beyond monotherapy across multiple technological platforms to optimize brain delivery and target multiple targets.

In fact, nanobodies are applied beyond monotherapy across multiple technological platforms to optimize brain delivery and target multiple targets. Nanobodies have been used on bispecific and trispecific antibody platforms, as well as in CRISPR/Cas9 editing and AI-driven technologies, to expand their applications.

Preclinical evidence indicates nanobodies can clear amyloid-β and tau, preserve synapses, and normalize biomarkers in Alzheimer's disease-related settings.

Recently, preclinical evidence has been mounting on the efficacy of nanobodies in clearing Aβ and tau, preserving synapses, and normalizing biomarkers.

Comparison with FDA-approved anti-amyloid-β monoclonal antibodies highlights translational gaps for Alzheimer's nanobody therapeutics including safety testing, half-life extension, and delivery optimization.

Comparison with FDA-approved anti-Aβ monoclonal antibodies (aducanumab, lecanemab, and donanemab) highlights opportunities and current translational gaps, including safety testing, half-life extension, and delivery optimization.

Nanobody applications in Alzheimer's disease remain preclinical and direct clinical evidence in patients is lacking.

However, all nanobody applications in AD are discussed strictly as preclinical therapeutic potential rather than established clinical therapies, and direct clinical evidence in patients with AD is still lacking.

Nanobodies are used beyond monotherapy across multiple technological platforms to optimize brain delivery and target multiple targets.

In fact, nanobodies are applied beyond monotherapy across multiple technological platforms to optimize brain delivery and target multiple targets. Nanobodies have been used on bispecific and trispecific antibody platforms, as well as in CRISPR/Cas9 editing and AI-driven technologies, to expand their applications.

Source: Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches.